Your browser is no longer supported. Please, upgrade your browser.
Settings
BHVN Biohaven Pharmaceutical Holding Company Ltd. daily Stock Chart
BHVN [NYSE]
Biohaven Pharmaceutical Holding Company Ltd.
Index- P/E- EPS (ttm)-5.22 Insider Own3.40% Shs Outstand34.68M Perf Week19.56%
Market Cap1.08B Forward P/E- EPS next Y-4.08 Insider Trans-45.65% Shs Float17.52M Perf Month31.98%
Income-124.20M PEG- EPS next Q-1.20 Inst Own46.00% Short Float4.94% Perf Quarter-3.61%
Sales- P/S- EPS this Y-532.90% Inst Trans0.35% Short Ratio2.58 Perf Half Y28.40%
Book/sh4.35 P/B7.18 EPS next Y27.70% ROA-102.20% Target Price36.40 Perf Year-
Cash/sh5.07 P/C6.16 EPS next 5Y- ROE-198.40% 52W Range17.00 - 39.51 Perf YTD15.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-20.93% Beta-
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low83.76% ATR1.66
Employees32 Current Ratio8.10 Sales Q/Q- Oper. Margin- RSI (14)67.34 Volatility7.87% 5.78%
OptionableYes Debt/Eq0.04 EPS Q/Q43.60% Profit Margin- Rel Volume2.32 Prev Close28.97
ShortableYes LT Debt/Eq0.04 EarningsNov 13 Payout- Avg Volume334.92K Price31.24
Recom1.70 SMA2012.93% SMA5022.02% SMA20013.49% Volume776,747 Change7.84%
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
Jan-18-18 03:00AM  Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist PR Newswire +7.58%
Jan-11-18 07:40AM  Wired News Biohaven Pharmaceutical Shares Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis Orally Dissolving Tablet ACCESSWIRE
Jan-09-18 03:00AM  Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet PR Newswire
Dec-21-17 03:00AM  Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder PR Newswire
Nov-27-17 03:00AM  Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant PR Newswire
Nov-20-17 07:40AM  Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine ACCESSWIRE
03:00AM  Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine PR Newswire
Nov-16-17 03:00AM  Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine PR Newswire +5.93%
Nov-14-17 06:02PM  Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results PR Newswire
Nov-13-17 03:00AM  Biohaven Expands Finance Team With Appointment Of Senior Vice President PR Newswire
Nov-06-17 03:00AM  Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223 PR Newswire
Nov-01-17 04:00AM  Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with ALS Benzinga
03:00AM  Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis (ALS) PR Newswire
Oct-30-17 03:00AM  Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute PR Newswire
Oct-26-17 07:30AM  Corporate News Blog - US FDA Green Signals Clinical Investigation of Biohaven Pharma's Trigriluzole For Treatment Of OCD ACCESSWIRE
Oct-25-17 03:00AM  Biohaven Adds Clifford Bechtold as Chief Operating Officer PR Newswire
Oct-24-17 03:00AM  Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder PR Newswire
Oct-03-17 04:25PM  Why This Biotech Suffered A 2-Day Headache On Rare-Disease Trial Investor's Business Daily -6.97%
Oct-02-17 12:24PM  Here's Why Biohaven Pharmaceutical Stock Fell as Much as 28.6% Today Motley Fool
06:30AM  Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial PR Newswire
Sep-15-17 03:00AM  Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease PR Newswire
Sep-11-17 03:00AM  Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference PR Newswire
Aug-30-17 07:30AM  [$$] Zinsli's Take: A Milestone for Post-IPO Companies Is In Sight The Wall Street Journal
Aug-14-17 06:44AM  Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results PR Newswire
Aug-07-17 03:00AM  Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 PR Newswire
Aug-04-17 03:00AM  Biohaven Appoints Julia P. Gregory to Board of Directors PR Newswire
Jul-31-17 03:00AM  Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine PR Newswire
Jul-24-17 03:00AM  Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine PR Newswire
Jul-18-17 03:00AM  PeptiDream and Kleo Pharmaceuticals Announce Collaboration Agreement to Develop Novel Immunotherapies for Oncology PR Newswire
Jul-13-17 03:00AM  Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs PR Newswire
Jul-12-17 09:50AM  IPO Market Back On Track: ETFs to Tap Zacks
Jul-09-17 12:22PM  [$$] Clinical Development News, July 3-7 The Wall Street Journal
Jul-06-17 03:00AM  Biohaven's BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome PR Newswire
Jun-23-17 05:00PM  Biohaven Added to Russell Microcap® Index PR Newswire
Jun-22-17 03:00AM  Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives PR Newswire -5.00%
Jun-19-17 04:33PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
04:27PM  Biotech IPO Rides Sectorwide Boom To Breakout Monday Investor's Business Daily
Jun-16-17 06:00AM  Biohaven Pharmaceuticals Reports First Quarter 2017 Financial and Business Results PR Newswire +10.83%
Jun-09-17 03:00AM  Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer PR Newswire
May-30-17 03:00AM  Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole PR Newswire
May-19-17 07:13PM  [$$] Clinical Development News, May 15-19 The Wall Street Journal
May-18-17 07:30AM  [$$] Some Biotech Companies Making the Cut in Narrower IPO Market The Wall Street Journal
May-15-17 03:00AM  Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA PR Newswire
May-11-17 10:40PM  Biohaven Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
May-09-17 09:29AM  Opening Bell, May 9, 21017 CNBC Videos
09:15AM  Today's Bell Ringer, May 9, 2017 CNBC Videos
May-07-17 10:31AM  IPOs This Week: Manufacturing Firm Gardner Denver Seeks $1 Billion 24/7 Wall St.
May-04-17 08:56AM  Biohaven Pharmaceutical raises $168 million in initial public offering MarketWatch
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. The company also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Doogan DeclanDirectorJan 18Sale28.2227,935788,2541,396,002Jan 18 06:57 PM
Doogan DeclanDirectorJan 17Sale26.5961,2561,628,6891,423,937Jan 18 06:57 PM
Doogan DeclanDirectorJan 16Sale26.6138,8671,034,3541,485,193Jan 18 06:57 PM
Bailey GregoryDirectorJan 16Sale26.5240,0001,060,8002,590,101Jan 18 06:37 PM
Doogan DeclanDirectorJan 12Sale26.3933,442882,5931,178,058Jan 12 07:00 PM
Doogan DeclanDirectorJan 11Sale26.2848,1381,265,2811,211,500Jan 12 07:00 PM
Doogan DeclanDirectorJan 10Sale27.6940,3621,117,6641,259,638Jan 12 07:00 PM
Berman RobertChief Medical OfficerJan 10Sale27.5235,000963,133466,000Jan 12 06:59 PM
PORTAGE BIOTECH INC.10% OwnerJan 09Sale30.0856,1571,688,9556,216,619Jan 09 06:23 PM
PORTAGE BIOTECH INC.10% OwnerJan 08Sale30.025,728171,9446,272,776Jan 09 06:23 PM
PORTAGE BIOTECH INC.10% OwnerJan 05Sale30.0322,996690,6736,278,504Jan 09 06:23 PM
Bailey GregoryDirectorJan 04Sale28.7716,976488,4001,170,299Jan 05 08:05 PM
PORTAGE BIOTECH INC.10% OwnerJan 04Sale28.624,350124,504124,371Jan 05 10:29 AM
PORTAGE BIOTECH INC.10% OwnerJan 03Sale28.6135,6501,020,0716,305,850Jan 04 04:15 PM
Bailey GregoryDirectorJan 03Sale28.6833,024947,1281,187,275Jan 05 08:05 PM
Gentile KimberlyVP of OperationsJan 02Option Exercise0.615,0003,0505,000Jan 03 05:28 PM
Gentile KimberlyVP of OperationsJan 02Sale27.605,000138,0000Jan 03 05:28 PM
Bailey GregoryDirectorDec 20Sale26.3139,4301,037,2901,220,299Dec 22 05:58 PM
Berman RobertChief Medical OfficerDec 19Sale24.1010,000241,000494,000Dec 20 05:57 PM
Berman RobertChief Medical OfficerDec 11Sale21.2825,000532,000502,000Dec 14 07:08 AM
Gentile KimberlyVP of OperationsDec 01Option Exercise0.615,0003,0505,000Dec 05 04:02 PM
Gentile KimberlyVP of OperationsDec 01Sale21.995,000109,9620Dec 05 04:02 PM
Bailey GregoryDirectorNov 30Sale25.473,03077,1741,259,729Dec 01 07:27 PM
Bailey GregoryDirectorNov 29Sale25.486,940176,8311,262,759Dec 01 07:27 PM
Bailey GregoryDirectorNov 27Sale25.9220,000518,4001,269,699Nov 28 07:19 PM
Bailey GregoryDirectorNov 24Sale26.0260015,6121,289,699Nov 28 07:19 PM
Berman RobertChief Medical OfficerNov 14Sale24.4433,664822,627522,000Nov 14 05:51 PM
Berman RobertChief Medical OfficerNov 13Sale25.6246,5871,193,380548,932Nov 14 05:51 PM
Engelhart JamesChief Financial OfficerNov 10Option Exercise0.618,9385,45212,514Nov 14 05:52 PM
Engelhart JamesChief Financial OfficerNov 10Sale26.288,938234,8913,576Nov 14 05:52 PM
Berman RobertChief Medical OfficerNov 10Sale26.3152,3261,376,697586,201Nov 14 05:51 PM
Engelhart JamesChief Financial OfficerNov 09Option Exercise0.6121,60013,17625,176Nov 14 05:52 PM
Berman RobertChief Medical OfficerNov 09Sale26.6027,423729,361628,062Nov 14 05:51 PM
Engelhart JamesChief Financial OfficerNov 09Sale26.7021,600576,6703,576Nov 14 05:52 PM
Tilton JohnChief Commercial OfficerNov 01Option Exercise9.2930,000278,70030,000Nov 02 05:55 PM
Gentile KimberlyVP of OperationsNov 01Option Exercise0.615,0003,0505,000Nov 02 05:57 PM
Gentile KimberlyVP of OperationsNov 01Sale29.285,000146,3850Nov 02 05:57 PM
Tilton JohnChief Commercial OfficerNov 01Sale29.2530,000877,5860Nov 02 05:55 PM
Coric VladChief Executive OfficerNov 01Sale29.2450,0001,462,203575,000Nov 02 05:54 PM
Coric VladChief Executive OfficerOct 31Sale29.50100,0002,949,632600,000Nov 02 05:54 PM